To ensure the in vivo suppressive potential of systemic administration of the IL-4-activated BMDM, we used a mouse model of multiple sclerosis, which represents an inflammatory T-cell mediated CNS disease that can be arrested by systemic anti-inflammatory treatment. The gene discussed is IL4; the disease is multiple sclerosis.